keyword
MENU ▼
Read by QxMD icon Read
search

Protocol chemotherapy for lung cancer

keyword
https://www.readbyqxmd.com/read/28287519/endobronchial-ultrasound-guided-intratumoral-injection-of-cisplatin-for-the-treatment-of-isolated-mediastinal-recurrence-of-lung-cancer
#1
Hiren J Mehta, Michael A Jantz
Isolated hilar and mediastinal recurrence (IMHR) following external beam radiation therapy (EBRT) in patients with lung cancer is common. These patients do not have many treatment options and are usually offered palliative chemotherapy or best supportive care. Endobronchial ultrasound (EBUS)-guided intratumoral injection of cisplatin (ITC) is a novel approach for these patients. The procedure is performed under conscious sedation. The lesion is located with a bronchoscopy using EBUS, and a 22-gauge EBUS needle is advanced through the working channel of the scope and locked in position...
February 12, 2017: Journal of Visualized Experiments: JoVE
https://www.readbyqxmd.com/read/28244415/a-randomized-phase-2-trial-of-prophylactic-manuka-honey-for-the-reduction-of-chemoradiation-therapy-induced-esophagitis-during-the-treatment-of-lung-cancer-results-of-nrg-oncology-rtog-1012
#2
Shannon E Fogh, Snehal Deshmukh, Lawrence B Berk, Amylou C Dueck, Kevin Roof, Sherif Yacoub, Thomas Gergel, Kevin Stephans, Andreas Rimner, Albert DeNittis, John Pablo, Justin Rineer, Terence M Williams, Deborah Bruner
PURPOSE: Randomized trials have shown that honey is effective for the prevention of radiation-induced mucositis in head and neck cancer patients. Because there is no efficacious preventative for radiation esophagitis in lung cancer patients, this trial compared liquid honey, honey lozenges, and standard supportive care for radiation esophagitis. METHODS: The patients were stratified by percentage of esophagus receiving specific radiation dose (V60 Gy esophagus <30% or ≥30%) and were then randomized between supportive care, 10 mL of liquid manuka honey 4 times a day, and 2 lozenges (10 mL of dehydrated manuka honey) 4 times a day during concurrent chemotherapy and radiation therapy...
March 15, 2017: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/28181415/a-phase-ii-trial-of-concurrent-chemotherapy-with-intravenous-cisplatin-and-vinorelbine-and-radiotherapy-followed-by-consolidation-chemotherapy-with-oral-vinorelbine-in-locally-advanced-non-small-cell-lung-cancer-nsclc-the-concave-study
#3
Brett Gm Hughes, Elizabeth Ahern, Margot Lehman, Gary Pratt, Margaret Dauth, Wendy Pritchard, Leesa Wockner, Keith Horwood
AIM: Despite recent advances, outcomes for patients with stage III non-small cell lung cancer (NSCLC) with concurrent chemoradiotherapy (CRT) remain poor. We evaluated the combination of ciplatin/vinorelbine and concurrent thoracic radiotherapy followed by consolidation oral vinorelbine in this phase II study. METHODS: Eligible patients with unresectable stage III NSCLC received cisplatin intravenous (IV) 40 mg/m(2) and vinorelbine IV 20 mg/m(2) on days 1, 8, 22 and 29 concurrent with thoracic radiotherapy of 60 Gy in 30 fractions...
February 9, 2017: Asia-Pacific Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28156492/food-as-medicine-a-randomized-controlled-trial-rct-of-home-delivered-medically-tailored-meals-hdmtm-on-quality-of-life-qol-in-metastatic-lung-and-non-colorectal-gi-cancer-patients
#4
Raymond Mailhot Vega, Lisa Zullig, Alissa Wassung, Dorella Walters, Noah Berland, Kevin Lee Du, Jiyoung Ahn, Cynthia G Leichman, Deirdre Jill Cohen, Ping Gu, Abraham Chachoua, Lawrence P Leichman, Karen Pearl, Peter B Schiff
155 Background: Malnutrition incidence in cancer approaches 85%, disproportionately burdening those with lung, GI, and advanced stage cancers. Malnourished patients have impaired chemotherapy response, shorter survival, longer hospital stays, and decreased QoL. Home delivered meals are nutritional interventions that improve patient well-being, nutrition, and lower healthcare costs in the elderly but have not been studied as an intervention in cancer patients. HDMTM are nutritionist prescribed home delivered meals tailored to patient's symptoms, co-morbidities, and health needs...
October 9, 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28089762/long-terms-results-of-a-trial-of-concurrent-chemotherapy-and-escalating-doses-of-radiation-for-unresectable-non-small-cell-lung-cancer-ncctg-n0028-alliance
#5
Steven E Schild, Shauna L Hillman, Angelina D Tan, Helen J Ross, William L McGinnis, Yolanda A Garces, David L Graham, Alex A Adjei, James R Jett
INTRODUCTION OR HYPOTHESIS: This phase I/II trial was originally designed to determine the maximally tolerated dose(MTD) of thoracic radiotherapy(TRT) as part of a combined modality approach. This report includes the long-term outcome of patients treated on this study. The phase II portion was never completed as RTOG-0617 opened before it was concluded. METHODS: The MTD was defined as 74Gy in 37 fractions in this study. Twenty-five patients with unresectable non-small cell lung cancer(NSCLC) were treated with 2Gy daily fractions and concurrent weekly carboplatin and paclitaxel...
January 12, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28081545/mathematical-optimisation-of-the-cisplatin-plus-etoposide-combination-for-managing-extensive-stage-small-cell-lung-cancer-patients
#6
C Faivre, R El Cheikh, D Barbolosi, F Barlesi
BACKGROUND: Small-cell lung cancer (SCLC) represents one of the most aggressive forms of lung cancer. Despite the fair sensitivity of SCLC to chemotherapy and radiotherapy, the current standard treatment regimens have modest survival rates and are associated with potential life-threatening adverse events. Therefore, research into new optimised regimens that increase drug efficacy while respecting toxicity constraints is of primary importance. METHODS: A PK/PD model for the combination of cisplatin and etoposide to treat extensive-stage SCLC patients was generated...
January 2017: British Journal of Cancer
https://www.readbyqxmd.com/read/28073986/does-the-addition-of-postoperative-radiotherapy-to-adjuvant-chemotherapy-offer-any-benefit-in-patients-with-non-small-cell-lung-cancer-and-mediastinal-lymphadenopathy
#7
Georgios Koulaxouzidis, Levon Toufektzian, Leanne Ashrafian, Lukacs Veres
A best evidence topic in thoracic surgery was written according to a structured protocol. The question addressed was whether the addition of postoperative radiotherapy (PORT) to adjuvant chemotherapy offers any benefit in patients undergoing curative resection for non-small cell lung cancer found to harbour mediastinal lymphadenopathy. A total of 77 papers were identified using the reported search, of which 11 represented the best evidence to answer the clinical question. Only studies reporting on survival data of patients receiving adjuvant chemotherapy with and without PORT were included in this analysis...
January 10, 2017: Interactive Cardiovascular and Thoracic Surgery
https://www.readbyqxmd.com/read/28027103/neoadjuvant-approach-for-nonsmall-cell-lung-cancer-overview-of-the-current-issues
#8
Giulio Francolini, Katia Ferrari, Vieri Scotti
PURPOSE OF REVIEW: Despite the large numbers of studies, role of neoadjuvant chemotherapy and neoadjuvant chemoradiotherapy is debated. This approach would increase resectability in locally advanced patients, and improve surgical outcome in resectable patients. Thus, an overview of recent literature is relevant to highlight the current issues. RECENT FINDINGS: Literature in the previous year mainly focused on overall treatment strategy, radiotherapy technique, role of radiological response and metabolic imaging, and biological agents in this setting...
March 2017: Current Opinion in Oncology
https://www.readbyqxmd.com/read/27920688/complete-and-sustained-response-with-a-doublet-chemotherapy-protocol-in-an-81-year-old-patient-with-metastatic-breast-cancer
#9
Taynah Cascaes Puty, Gabriel S A Brito, Mariana S Dias, Henrique C Miranda, Juliana R Chaves, Heryvelton L Freitas, Luís E W Carvalho
Metastatic breast cancer (MBC) entails an overall 5-year survival of approximately 25%. The choice of therapy is influenced by expression of the HER2 gene and hormone receptors, by a disease-free interval, and by age. The use of paclitaxel combined with gemcitabine (doublet protocol) has shown efficacy as first-line treatment for MBC in either initial or maintenance therapy when compared to monotherapy with paclitaxel. There is evidence showing that the doublet protocol is a good alternative to maintenance therapy in women under 50 years old...
September 2016: Case Reports in Oncology
https://www.readbyqxmd.com/read/27846903/prontox-proton-therapy-to-reduce-acute-normal-tissue-toxicity-in-locally-advanced-non-small-cell-lung-carcinomas-nsclc-study-protocol-for-a-randomised-controlled-trial
#10
Sebastian Zschaeck, Monique Simon, Steffen Löck, Esther G C Troost, Kristin Stützer, Patrick Wohlfahrt, Steffen Appold, Sebastian Makocki, Rebecca Bütof, Christian Richter, Michael Baumann, Mechthild Krause
BACKGROUND: Primary radiochemotherapy with photons is the standard treatment for locally advanced-stage non-small cell lung cancer (NSCLC) patients. Acute radiation-induced side effects such as oesophagitis and radiation pneumonitis limit patients' quality of life, and the latter can be potentially life-threatening. Due to its distinct physical characteristics, proton therapy enables better sparing of normal tissues, which is supposed to translate into a reduction of radiation-induced side effects...
November 15, 2016: Trials
https://www.readbyqxmd.com/read/27833519/monocytopenia-induction-by-vinorelbine-cisplatin-and-doxorubicin-in-breast-non-small-cell-lung-and-cervix-cancer-patients
#11
Taha Nazir, Nida Taha, Azahrul Islam, Suraj Abraham, Adeel Mahmood, Mazhar Mustafa
BACKGROUND: The neoplasm is still a potential threat for breast, Non-Small Cell Lung (NSCL) and cervix cancer patients. Those gradually invade into other body organs, inducing complex pathological complications. Whereas, the anticancer drugs suppress the bone marrow, resulting serious hematological toxicities. Thus, the monocytic toxicity may the chance of infections, particularly in AID's patients. OBJECTIVE: We aimed this retrospective study to investigate the monocytopenia induced by vinorelbine following chemotherapy in cancer patients...
October 2016: International Journal of Health Sciences
https://www.readbyqxmd.com/read/27825799/combination-of-2-deoxy-d-glucose-and-metformin-for-synergistic-inhibition-of-non-small-cell-lung-cancer-a-reactive-oxygen-species-and-p-p38-mediated-mechanism
#12
Xiao-Bin Hou, Ting-Hui Li, Zhi-Peng Ren, Yang Liu
Targeting metabolism of lung cancer cells is a promising methodology for the treatment of lung cancer. In this regard, 2-Deoxy d-glucose (2-dDG) has been reported to inhibit cell proliferation by intervening the glycolytic pathway. However, phase I clinical trial of 2-dDG demonstrated cardiac side effects at higher dosage. Metformin (Met), on the other hand, has been reported to improve pathological response to chemotherapy in non-small cell lung cancer (NSCLC) patients. In this study, we propose that combination therapy of 2-dDG with Met will demonstrate enhanced cytotoxicity than either compound alone...
December 2016: Biomedicine & Pharmacotherapy, Biomédecine & Pharmacothérapie
https://www.readbyqxmd.com/read/27798860/histone-deacetylase-inhibitors-a-novel-therapeutic-weapon-against-medullary-thyroid-cancer
#13
REVIEW
Christos Damaskos, Serena Valsami, Eleftherios Spartalis, Efstathios A Antoniou, Periklis Tomos, Stefanos Karamaroudis, Theofano Zoumpou, Vasilios Pergialiotis, Konstantinos Stergios, Constantinos Michaelides, Konstantinos Kontzoglou, Despina Perrea, Nikolaos Nikiteas, Dimitrios Dimitroulis
BACKGROUND/AIM: Medullary thyroid cancer (MTC) is highly malignant, metastatic and recurrent, remaining generally incurable, and responsible for approximately 14% of all thyroid carcinoma-related deaths. MTC can metastasize to lymph nodes, trachea and distant organs, such as brain, lungs, liver and bones. MTC cells are resistant to chemotherapy and traditional external therapies are not showing definite clinical benefits. Scientists are trying to understand the molecular background of carcinogenesis and histone deacetylase (HDAC) seems to play a potential role to gene transcription...
2016: Anticancer Research
https://www.readbyqxmd.com/read/27747006/patient-evaluation-for-rapid-pleurodesis-of-malignant-pleural-effusions
#14
Rebecca Krochmal, Chakravarthy Reddy, Lonny Yarmus, Neeraj R Desai, David Feller-Kopman, Hans J Lee
BACKGROUND: Malignant pleural effusions (MPEs) represent advanced stage disease with potentially significant patient discomfort due to dyspnea. Palliative management options include repetitive thoracenteses, placement of a tunneled pleural catheter (TPC), chemical pleurodesis, or some combination of these procedures. The rapid pleurodesis procedure combines thoracoscopic talc pleurodesis and insertion of a TPC at the same time with the goals of reducing both the length of hospitalization and the duration of catheter use...
September 2016: Journal of Thoracic Disease
https://www.readbyqxmd.com/read/27730801/comparison-of-concurrent-chemoradiotherapy-versus-sequential-radiochemotherapy-in-patients-with-completely-resected-non-small-cell-lung-cancer
#15
Hwan-Ik Kim, O Kyu Noh, Young-Taek Oh, Mison Chun, Sang-Won Kim, Oyeon Cho, Jaesung Heo
PURPOSE: Our institution has implemented two different adjuvant protocols in treating patients with non-small cell lung cancer (NSCLC): chemotherapy followed by concurrent chemoradiotherapy (CT-CCRT) and sequential postoperative radiotherapy (PORT) followed by postoperative chemotherapy (POCT). We aimed to compare the clinical outcomes between the two adjuvant protocols. MATERIALS AND METHODS: From March 1997 to October 2012, 68 patients were treated with CT-CCRT (n = 25) and sequential PORT followed by POCT (RT-CT; n = 43)...
September 2016: Radiation Oncology Journal
https://www.readbyqxmd.com/read/27597285/current-patterns-of-care-for-patients-with-extensive-stage-small-cell-lung-cancer-survey-of-us-radiation-oncologists-on-their-recommendations-regarding-thoracic-consolidation-radiotherapy
#16
Timur Mitin, Aditya Jain, Catherine Degnin, Yiyi Chen, Mark Henderson, Charles R Thomas
OBJECTIVES: Current National Comprehensive Cancer Network (NCCN) guidelines recommend thoracic consolidation radiation therapy (TCRT) for patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC) with response to systemic chemotherapy, based on two randomized clinical trials, which varied in patient selection and radiation therapy doses administered. The current pattern of practice among US radiation oncologists is unknown. MATERIALS AND METHODS: We have surveyed practicing US radiation oncologist via a short online questionnaire...
October 2016: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/27592612/pulmonary-anthracosis-mimicking-lung-metastases-in-pediatric-rhabdomyosarcoma
#17
Gabrielle Karpinsky, Malgorzata Anna Krawczyk, Aleksandra Fatyga, Ewa Izycka-Swieszewska, Miroslawa Dubaniewicz-Wybieralska, Dagmara Szmyd, Monika Luboch-Furmanczyk, Ewa Bien
Although childhood rhabdomyosarcoma typically metastasizes to lungs, various processes may mimic metastatic etiology. Described herein is the case of an 8½-year-old boy with orbital embryonal rhabdomyosarcoma (RME) in whom three small foci were detected within both lungs on computed tomography. The lesion number and size, however, did not fulfil the Cooperative Weichteilsarkom Study Group 2006 protocol criteria for lung metastasis. Chemotherapy for localized RME produced primary tumor regression and vanishing of the left lung lesion...
October 2016: Pediatrics International: Official Journal of the Japan Pediatric Society
https://www.readbyqxmd.com/read/27523409/-radiotherapy-in-cancers-of-the-oesophagus-the-gastric-cardia-and-the-stomach
#18
G Créhange, F Huguet, L Quero, T V N'Guyen, X Mirabel, T Lacornerie
Localized oesophageal and gastric cancers have a poor prognosis. In oesophageal cancer, external radiotherapy combined with concomitant chemotherapy is accepted as part of the therapeutic armamentarium in a curative intent in the preoperative setting for resectable tumours; or without surgery in inoperable patients or non-resectable tumours due to wide local and/or regional extension. Data from the literature show conflicting results with no clinical evidence in favour of either a unique dose protocol or consensual target volume definition in the setting of exclusive chemoradiation...
September 2016: Cancer Radiothérapie: Journal de la Société Française de Radiothérapie Oncologique
https://www.readbyqxmd.com/read/27497829/trastuzumab-emtansine-in-her2-recurrent-metastatic-non-small-cell-lung-cancer-study-protocol
#19
Kadoaki Ohashi, Katsuyuki Hotta, Taizo Hirata, Keisuke Aoe, Toshiyuki Kozuki, Kiichiro Ninomiya, Hiroe Kayatani, Hiroyuki Yanai, Shinichi Toyooka, Shiro Hinotsu, Minoru Takata, Katsuyuki Kiura
The treatment outcome has been unsatisfactory for patients with non-small-cell lung cancer (NSCLC) refractory to standard first-line chemotherapy. Trastuzumab emtansine (T-DM1), an anti-HER2 antibody conjugated with a vinca alkaloid, has been approved for clinical use in HER2+ breast cancer in many countries. Approximately 5% of NSCLC tumors possess HER2 alterations, and T-DM1 has shown excellent antitumor effects against HER2+ lung cancer cell lines in preclinical models. Therefore, we hypothesized that T-DM1 could significantly inhibit the growth of HER2+ lung cancers...
July 9, 2016: Clinical Lung Cancer
https://www.readbyqxmd.com/read/27489157/live-cumulative-network-meta-analysis-protocol-for-second-line-treatments-in-advanced-non-small-cell-lung-cancer-with-wild-type-or-unknown-status-for-epidermal-growth-factor-receptor
#20
Perrine Créquit, Ludovic Trinquart, Philippe Ravaud
INTRODUCTION: Many second-line treatments for advanced non-small-cell lung cancer (NSCLC) have been assessed in randomised controlled trials, but which treatments work the best remains unclear. Novel treatments are being rapidly developed. We need a comprehensive up-to-date evidence synthesis of all these treatments. We present the protocol for a live cumulative network meta-analysis (NMA) to address this need. METHODS AND ANALYSIS: We will consider trials of second-line treatments in patients with advanced NSCLC with wild-type or unknown epidermal growth factor receptor status...
2016: BMJ Open
keyword
keyword
109129
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"